Overview

Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
An intestinal hormone called Glucose-dependent Insulinotropic Polypeptide (GIP) is released into the blood immediately after ingestion of a meal and plays an important role in regulating blood sugar levels. However, GIP is not active in persons with type 2 diabetes mellitus (T2DM) which is also known as adult onset or non-insulin-dependent diabetes. This study is being conducted to determine whether a hormone called xenin-25 can restore the activity of GIP in persons with T2DM.
Phase:
Phase 1
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Gastric Inhibitory Polypeptide